EUVIMEDEUVIMED entdecken
ValidierungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Prognostic Nomogram for Ovarian Cancer Patients on First‐Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study

Shuran Tan iD, Siyu Yang iD, Xuerui Duan iD, Yu Zhang iD

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71891 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 22.05.2026. Verfasst von Shuran Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: Nomograms, Ovarian Neoplasms, Maintenance Chemotherapy, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To develop and validate a prognostic nomogram that integrates clinical variables and biomarker statuses for predicting progression‐free survival (PFS) and overall survival (OS) in patients with advanced epithelial ovarian cancer (OC) receiving first‐line poly (ADP‐ribose) polymerase inhibitor (PARPi) maintenance therapy.

Methods

Clinical data from 145 OC patients who received first‐line PARPi maintenance therapy from August 2018 to May 2024 were retrospectively analyzed. Univariate and multivariate regression analyses were performed to identify the predictive factors. A nomogram was constructed using a multivariate Cox regression model.

Results

Patients with OC who received first‐line PARPi maintenance treatment showed improved PFS (median PFS: 48.53 months) and OS. Cox regression analysis identified several independent prognostic factors for prolonged PFS, including BRCA mutations, R0 resection (no residual disease), FIGO stage III (vs. IV), and a higher CA‐125 elimination rate constant (KELIM) score (KELIM > 1). Additionally, BRCA mutations and younger age were significant predictors of better OS. Analysis of subsequent treatment in patients who experienced recurrence revealed that platinum‐based second‐line chemotherapy combined with bevacizumab improved outcomes, whereas a longer duration of PARPi therapy (> 12 months) appeared to be associated with poorer prognosis.

Conclusion

This study establishes and validates the nomogram that integrates clinical factors (FIGO Stage, Residual Disease, and Age) with biomarkers (BRCA and KELIM) to predict outcomes in patients with advanced OC receiving First‐Line PARPi maintenance therapy. Furthermore, our finding suggest that an extended duration of PARPi treatment may be a risk factor for subsequent treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NomogramsOvarian NeoplasmsMaintenance ChemotherapyPoly(ADP-ribose) Polymerase InhibitorsCarcinoma, Ovarian EpithelialRetrospective StudiesBiomarkers, TumorPredictive Value of TestsProgression-Free SurvivalSurvival RateNeoplasm StagingAge FactorsTreatment OutcomeHumansFemaleYoung AdultAdultMiddle AgedAged

Stichwörter der Autor:innen

PARP inhibitornomogramovarian cancerprognostic factors

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
  • Gynecological Oncology Research and Engineering Center of Hunan Province, Xiangya Hospital, Changsha, Hunan, People's Republic of China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, People's Republic of China.

ORCID-Profile: Shuran Tan, Siyu Yang, Xuerui Duan, Yu Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tan, S., Yang, S., Duan, X., & Zhang, Y. (2026). Prognostic Nomogram for Ovarian Cancer Patients on First‐Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71891

Vancouver

Tan S, Yang S, Duan X, Zhang Y. Prognostic Nomogram for Ovarian Cancer Patients on First‐Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71891

BibTeX
@article{Tan2026,
  author = {Tan, Shuran and Yang, Siyu and Duan, Xuerui and Zhang, Yu},
  title = {Prognostic Nomogram for Ovarian Cancer Patients on First‐Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71891}
}
Kostenlos starten →